Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS

NCT02185820 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.

NCT NCT02185820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02185820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS
Lead sponsor
European Myeloma Network B.V.
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2014
Completion date
January 31, 2023
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma